Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of CD208-positive cell infiltration in gastric cancer.
Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M, Shinchi H, Kijima Y, Natsugoe S. Ishigami S, et al. Cancer Immunol Immunother. 2010 Mar;59(3):389-95. doi: 10.1007/s00262-009-0758-8. Epub 2009 Sep 16. Cancer Immunol Immunother. 2010. PMID: 19760221 Free PMC article.
Prognostic value of CCR7 expression in gastric cancer.
Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uenosono Y, Arigami T, Matsumoto M, Okumura H, Hokita S, Aikou T. Ishigami S, et al. Hepatogastroenterology. 2007 Jun;54(76):1025-8. Hepatogastroenterology. 2007. PMID: 17629031
Clinical implication of CXCL12 expression in gastric cancer.
Ishigami S, Natsugoe S, Okumura H, Matsumoto M, Nakajo A, Uenosono Y, Arigami T, Uchikado Y, Setoyama T, Arima H, Hokita S, Aikou T. Ishigami S, et al. Ann Surg Oncol. 2007 Nov;14(11):3154-8. doi: 10.1245/s10434-007-9521-6. Epub 2007 Jul 26. Ann Surg Oncol. 2007. PMID: 17653799
HLA-class I expression in gastric cancer.
Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T. Ishigami S, et al. J Surg Oncol. 2008 Jun 1;97(7):605-8. doi: 10.1002/jso.21029. J Surg Oncol. 2008. PMID: 18459158
Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, Kita Y, Kurahara H, Okumura H, Matsumoto M, Kijima Y, Natsugoe S. Ishigami S, et al. Anticancer Res. 2010 Jun;30(6):2453-7. Anticancer Res. 2010. PMID: 20651407
Clinical implication of CD166 expression in gastric cancer.
Ishigami S, Ueno S, Arigami T, Arima H, Uchikado Y, Kita Y, Sasaki K, Nishizono Y, Omoto I, Kurahara H, Matsumoto M, Kijima Y, Natsugoe S. Ishigami S, et al. J Surg Oncol. 2011 Jan 1;103(1):57-61. doi: 10.1002/jso.21756. J Surg Oncol. 2011. PMID: 20886585
Prognostic impact of CD168 expression in gastric cancer.
Ishigami S, Ueno S, Nishizono Y, Matsumoto M, Kurahara H, Arigami T, Uchikado Y, Setoyama T, Arima H, Yoshiaki K, Kijima Y, Kitazono M, Natsugoe S. Ishigami S, et al. BMC Cancer. 2011 Mar 24;11:106. doi: 10.1186/1471-2407-11-106. BMC Cancer. 2011. PMID: 21435222 Free PMC article.
Mesothelin expression correlates with prolonged patient survival in gastric cancer.
Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S. Baba K, et al. Among authors: ishigami s. J Surg Oncol. 2012 Feb;105(2):195-9. doi: 10.1002/jso.22024. Epub 2011 Jul 20. J Surg Oncol. 2012. PMID: 21780126
325 results